Congenital Heart Disease – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Congenital Heart Disease – Drugs In Development, 2024 report and make more profitable business decisions.
Congenital heart disease is an impairment of the heart’s structure that is present at birth. It may change the normal flow of blood through the heart. It is the most common type of birth defect, occurring in about 1% of live births in the US. There are different types of congenital heart defects; the most common involve the inside walls of the heart, the valves of the heart, or the large blood vessels that carry blood to and from the heart. Some defects are simple and require no treatment, while others are critical and require treatment soon after birth.
The Congenital Heart Disease drugs in development market research report provide comprehensive information on the therapeutics under development for Congenital Heart Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Congenital Heart Disease and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Congenital Heart Disease | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 9 molecules, with 9 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Congenital Heart Disease therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Congenital Heart Disease pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Congenital Heart Disease treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Angelini Pharma SpABayer AG
Capricor Therapeutics Inc
HeartWorks Inc
Longeveron Inc
Mesoblast Ltd
Metcela Inc
Mezzion Pharma Co Ltd
PLx Pharma Winddown Corp
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Congenital Heart Disease reports